DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+19.48%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$161M
AUM Growth
+$161M
(+15%)
Cap. Flow
-$3.12M
Cap. Flow
% of AUM
-1.94%
Top 10 Holdings %
Top 10 Hldgs %
48.45%
Holding
88
New
12
Increased
11
Reduced
19
Closed
15
Top Buys
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$3.35M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.16M |
| 3 |
DexCom
DXCM
|
$2.81M |
| 4 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$2.03M |
| 5 |
Kura Oncology
KURA
|
$1.58M |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$3.82M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$2.48M |
| 3 |
SPNC
Spectranetics Corp
SPNC
|
$2.15M |
| 4 |
Sangamo Therapeutics
SGMO
|
$1.98M |
| 5 |
CLLS
Cellectis
CLLS
|
$1.97M |
Sector Composition
| 1 | Healthcare | 80.09% |